Business Wire

NC-PERCONA

20.8.2024 14:31:27 CEST | Business Wire | Press release

Share
Percona Augments Corporate Governance with the Appointment of Two New Independent Directors

Percona, a global leader in enterprise-grade open source database software and services, today announced the addition of two preeminent technology business leaders – John Newton, Co-Founder of Alfresco and Documentum, and Rob Young, a veteran of the open source software ecosystem – as independent directors to its board. The appointments expand the wealth of business strategy, industry expertise and strategic counsel the Percona board offers CEO Ann Schlemmer and her leadership team.

John Newton brings over 40 years of experience in the enterprise software industry, having played a pivotal role in the development and success of numerous companies. A serial entrepreneur, John co-founded Documentum, which was acquired by EMC in 2003, and Alfresco, an open source platform for information management, which had a successful exit with its sale to Hyland Software in 2020. John began his career as one of the founding engineers at Ingres Corporation, where he led the development of their database management system. His innovative contributions to data and information management have earned him several prestigious awards, including recognition as a Technology Pioneer at the World Economic Forum in Davos in 2006 and the Award of Merit from the Association for Intelligent Information Management (AIIM) in 2023. John holds a BS in Electrical Engineering and Computer Science from the University of California, Berkeley, and has served on the boards of several leading companies, including Alfresco, Wideworks, and AIIM.

Rob Young is a seasoned business and technology executive with four decades of experience in building and delivering enterprise solutions through an open source development and delivery model. During his career, Rob has held key technical and leadership positions across various industries, including finance, transportation, healthcare, public utilities, and commercial software and services. Rob has been a driving force in establishing open source software as a trusted foundation for digital transformation. He was instrumental in developing growth strategies and business models focused on value-added differentiation and customer satisfaction in numerous strategic roles at MySQL AB, MongoDB, Percona, RedHat, and DigitalOcean. Notably, while with MySQL AB, Rob led the design, development, and delivery of MySQL Enterprise, which quadrupled the company's revenue in just two years and culminated in a $1 billion acquisition by Sun Microsystems. Rob holds a Bachelor of Science in Economics and Math from the University of Louisville and resides in Louisville, KY.

“We are honored to welcome John Newton and Rob Young to our board,” said Ann Schlemmer, CEO of Percona. “Their extensive experience and deep understanding of the industry will be invaluable as we continue to innovate and deliver world-class solutions to our customers. Their leadership and vision will be crucial as we navigate the opportunities and challenges ahead, ensuring we maintain the highest standards of corporate governance.”

These appointments come at a pivotal time for Percona as the company reaffirms its commitment to cloud-native development with the introduction of Percona Everest and expands its footprint into the Redis ecosystem through its involvement with the Linux Foundation’s Valkey Project. With the addition of John Newton and Rob Young, Percona is well-positioned to accelerate growth and continue its mission of empowering enterprises with robust, reliable, and scalable open source database solutions.

About Percona

Percona is a world-class open source database software, support, and services company. The organization is dedicated to helping businesses ensure their databases — and the applications that depend on them — are secure, compliant, performant, and highly available. Through a unique combination of database expertise and enterprise-grade open source software, Percona empowers organizations with the freedom to choose, the freedom to create, and the freedom to innovate with speed as they grow. For more information, visit www.percona.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240815431864/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye